CN108813636A - Beneficial anahemin composition and its application - Google Patents
Beneficial anahemin composition and its application Download PDFInfo
- Publication number
- CN108813636A CN108813636A CN201811087728.7A CN201811087728A CN108813636A CN 108813636 A CN108813636 A CN 108813636A CN 201811087728 A CN201811087728 A CN 201811087728A CN 108813636 A CN108813636 A CN 108813636A
- Authority
- CN
- China
- Prior art keywords
- liver
- anahemin
- polypeptide
- fructus lycii
- sheep
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 230000009286 beneficial effect Effects 0.000 title claims abstract description 8
- 210000004185 liver Anatomy 0.000 claims abstract description 105
- 241001494479 Pecora Species 0.000 claims abstract description 73
- 229920001184 polypeptide Polymers 0.000 claims abstract description 67
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 62
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 59
- 230000008901 benefit Effects 0.000 claims abstract description 20
- 230000036541 health Effects 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 244000241838 Lycium barbarum Species 0.000 claims description 17
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 17
- 235000013399 edible fruits Nutrition 0.000 claims description 17
- 235000015468 Lycium chinense Nutrition 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 7
- 239000008280 blood Substances 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 12
- 210000004027 cell Anatomy 0.000 abstract description 8
- 210000005229 liver cell Anatomy 0.000 abstract description 7
- 230000008929 regeneration Effects 0.000 abstract description 6
- 238000011069 regeneration method Methods 0.000 abstract description 6
- 210000003734 kidney Anatomy 0.000 abstract description 5
- 239000000047 product Substances 0.000 abstract description 4
- 206010011224 Cough Diseases 0.000 abstract description 3
- 210000000988 bone and bone Anatomy 0.000 abstract description 3
- 238000001784 detoxification Methods 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 230000010224 hepatic metabolism Effects 0.000 abstract description 3
- 210000004072 lung Anatomy 0.000 abstract description 3
- 210000003205 muscle Anatomy 0.000 abstract description 3
- 231100000915 pathological change Toxicity 0.000 abstract description 3
- 230000036285 pathological change Effects 0.000 abstract description 3
- 230000008439 repair process Effects 0.000 abstract description 3
- 239000006228 supernatant Substances 0.000 abstract description 3
- 206010067125 Liver injury Diseases 0.000 abstract description 2
- 230000004438 eyesight Effects 0.000 abstract description 2
- 231100000234 hepatic damage Toxicity 0.000 abstract description 2
- 230000008818 liver damage Effects 0.000 abstract description 2
- 230000001681 protective effect Effects 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- 229940100688 oral solution Drugs 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 7
- 230000003908 liver function Effects 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000009849 deactivation Effects 0.000 description 6
- 230000007071 enzymatic hydrolysis Effects 0.000 description 6
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 6
- 235000017784 Mespilus germanica Nutrition 0.000 description 5
- 244000182216 Mimusops elengi Species 0.000 description 5
- 235000000560 Mimusops elengi Nutrition 0.000 description 5
- 235000007837 Vangueria infausta Nutrition 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000004332 deodorization Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003384 small molecules Chemical group 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 238000008715 DBil Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 101000693530 Staphylococcus aureus Staphylokinase Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000002912 waste gas Substances 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention belongs to technical field of health care food, and in particular to a kind of benefit anahemin composition is mainly made by following raw material：Fructus lycii and sheep liver polypeptide.The present invention also provides above-mentioned beneficial anahemin compositions to prepare the application on liver protecting health care product.Benefit anahemin composition provided by the present invention is using sheep liver polypeptide and fructus lycii as raw material, wherein contain stimulator of liver cell regeneration (HSS) in sheep liver polypeptide, it can cell cultured supernatant synthetic DNA and have the function of promote liver cell regeneration, enhance liver detoxification function, promote liver metabolism, repairs liver pathological changes cell, and be rich in ferro element, it is remarkably improved cell hemochrome, there is blood nourishing function；Fructus lycii can be nourishing liver and kidney, strengthening muscles and bones, nourishing blood for improving eyesight, moistening lung to arrest cough；The two is applied in combination, and has facilitation to the function of liver, has protective effect in the case where liver damage.
Description
Technical field
The invention belongs to technical field of health care food, and in particular to a kind of benefit anahemin composition and its application.
Background technique
With the development of modern society, rhythm of life is accelerated, and constantly, diet is unhealthy, excessive drinking, or often for dinner party
It stays up late, certain damage can be all caused to liver；On the other hand, with the variation of social environment, new synthesis medicament and chemistry
The increase of drug, patient's Long-term taking medicine medication, the toxic side effect of drug generate chemical lesion to liver again；Further, since work
Fast development, waste water and gas and the random of pesticide of industry arrange abuse, and the fresh class remains of pesticide such as vegetable and fruit is in the intracorporal storage of people
Product also results in the damage of liver, and therefore, how liver protecting is at very necessary very urgent research topic.
And Chinese tradition diet is particular about balance, compares high praise diet-therapy health-preserving, modern age doctor's Zhang Xichun exists《Join west in medicine inner feelings
Record》In just once pointed out：Food " clothes for patients it, not only treat disease, and can allay one's hunger；Not only allay one's hunger, more can be agreeable to the taste, suited the medicine to the illness with it, disease is certainly
It is gradually cured, i.e., does not suit the medicine to the illness, also suffer from without him ".Wherein, fructus lycii (Lycium barbarum) is a kind of help class rare Chinese medicine, first recorded in
《Sheng Nong's herbal classic》, it is listed in top grade, calls it：" long term usage heavily fortified point muscles and bones is made light of one's life by commiting suicide not old, resistance to cold and heat ".Fructus lycii is sweet in flavor, mild-natured, returns
Liver and kidney channel, has nourishing liver and kidney, benefiting shrewd head, moistening lung to arrest cough, anti-aging and other effects, and ancient Chinese medicine doctor treats deficiency of liver-blood, kidney
Yin deficiency is empty, just usually uses fructus lycii.
Polysaccharides rich in fructus lycii, polysaccharides are a kind of water-soluble polysaccharides, and relative molecular weight 68-200 is existing
It is existing many research shows that polysaccharides have promote immune, anti-aging, it is antitumor, remove free radical, be antifatigue, anti-radiation,
The effects of protect liver, reproductive function protection and improvement.But facts proved that, polysaccharides effect in protect liver is very slow, even if
Continuous oral fructus lycii 2 months, it is also difficult to observe curative effect.
Summary of the invention
It is an object of the present invention to provide a kind of beneficial anahemin composition and its applications, are being protected with solving polysaccharides
Curative effect is slow on protecting liver and unconspicuous problem.
According to an aspect of the invention, there is provided a kind of benefit anahemin composition, is mainly made by following raw material：Fructus lycii
With sheep liver polypeptide.Wherein, sheep liver polypeptide is small molecule, biologically active peptide.Small-molecular peptides are conducive to the suction of human body as a result,
Receipts, utilization and digestion.
In some embodiments, the weight ratio of fructus lycii and sheep liver polypeptide is 1 in the composition：0.7-1.3.It adopts as a result,
With the compounding of fructus lycii and sheep liver polypeptide, while in conjunction with the two Common advantages, the two mutually plays synergistic effect, advantageously promotes
Absorption and use of the body to effective component, wherein：
In fructus lycii, the mainly polysaccharides of liver protection effect is played, liver can be protected to escape injury, show as certain inhibition
Effect.And sheep liver polypeptide molecular weight, it can directly absorb and reach the organ of human body.It is pierced in sheep liver polypeptide rich in liver cell regeneration
Swash the factor (HSS), it can cell cultured supernatant synthetic DNA and have the function of promote liver cell regeneration, enhance liver detoxification function,
Promote liver metabolism, repairs liver pathological changes cell.Fructus lycii and sheep liver polypeptide, the former derives from plant, and the latter derives from animal,
The former is the effect of defence, and the latter is the effect repaired, and the two is arranged in pairs or groups mutually, is complementary to one another, and it is bright can preferably to play protect liver
Purpose effect.
Preferably, the weight ratio of fructus lycii and sheep liver polypeptide is 1 in the composition:1.
In some embodiments, sheep liver polypeptide is sheep liver polypeptid solution or sheep liver polypeptide powder.
Wherein, sheep liver polypeptid solution is prepared by the following method：
(1) it takes new fresh sheep liver, removes fat, blood impurities, when sufficiently being washed to no watery blood, with beater homogenate, system
At meat gruel, then according to 1:2~10 ratio is mixed with water, is stirred evenly, and adjusts pH8.0 with 20%~40% alkaline solution
~10.5, in 40 DEG C~65 DEG C addition small peptide special protein enzymes 0.5 ‰~5 ‰ (V/W), hydrolyzes 2~4 hours, obtain first time water
Solve liquid；
(2) it is 8~10 by first time hydrolyzate tune pH, compound protease is added and is digested；Compound protein enzyme dosage is
The 0.2%~1% of total protein used, 3~5h of enzymolysis time in step (1)；Enzyme deactivation after enzymatic hydrolysis, enzyme-removal temperature be 85~
100 DEG C, the enzyme deactivation time 10~20 minutes；Rear decoloring, filtering, filtrate, that is, sheep liver polypeptid solution are completed in enzyme deactivation.
Alternatively, sheep liver polypeptide powder is prepared by the following method：New fresh sheep liver → finely divided processing → enzymatic hydrolysis → de- hardship →
Decoloration → ultrafiltration → drying → sheep liver polypeptide powder；Wherein enzymatic hydrolysis uses neutral proteinase, takes off hardship using de- bitter enzyme, decoloration and deodorization is adopted
With active carbon, ultrafiltration is filtered using film, dry to use spray drying process；Resulting sheep liver polypeptide molecular weight is in 1000D or less (its
In, molecular weight is below in 500D, accounts for 87%).
In some embodiments, fructus lycii is wolfberry fruit powder or fructus lycii water extract.Wherein, wolfberry fruit powder can be crushed by pulverizer
At powder；Fructus lycii water extract preparation method is as follows：Medlar powder is broken into thick last, as in tool plug bottle, adds water, bath temperature
It is ultrasonically treated 45min under the conditions of 60 DEG C, filters, collects filtrate up to fructus lycii water extract.
According to another aspect of the present invention, above-mentioned beneficial anahemin composition is provided on preparing liver protecting health care product
Application, show as above-mentioned beneficial anahemin composition liver protecting oral solution is made.
Specifically, can weigh wolfberry fruit powder and sheep liver polypeptide powder by weight, be dissolved in water, can take.As every time
100mg wolfberry fruit powder and 1.2g sheep liver polypeptide powder (the sheep liver polypeptide of the generally 7-10% containing accounting in sheep liver polypeptide powder) are taken, 10ml is added
Water dissolution is made oral solution and takes.
If sheep liver polypeptid solution and fructus lycii water extract is taken to be prepared, it should be ensured that every 10 milliliters of solution contains
The sheep liver polypeptide of 70-130mg (preferably 100mg) and containing 70-130mg (preferably 100mg) fructus lycii water mention after water extract it is (standby
Note：It carries out water with the fructus lycii of 70-130mg to mention).
The application method of benefit anahemin composition provided by the present invention is：Oral solution is made by existing conventional method, often
It is secondary to take 10ml, it takes 1-2 times, takes in the morning and evening daily.
Benefit anahemin composition provided by the present invention wherein contains in sheep liver polypeptide using sheep liver polypeptide and fructus lycii as raw material
Stimulator of liver cell regeneration (HSS), it can cell cultured supernatant synthetic DNA and have the function of promote liver cell regeneration, enhancing
Liver detoxification function promotes liver metabolism, repairs liver pathological changes cell, and be rich in ferro element, is remarkably improved cell blood
Pigment has blood nourishing function；Fructus lycii can be nourishing liver and kidney, strengthening muscles and bones, nourishing blood for improving eyesight, moistening lung to arrest cough；The two is applied in combination, right
The function of liver has facilitation, has protective effect in the case where liver damage；Moreover, good effect is shown in terms of liver protection
Effect is fast.
Specific embodiment
The present invention will be further described in detail with reference to the specific embodiments.
Embodiment 1
A kind of benefit anahemin composition, is made of wolfberry fruit powder and sheep liver polypeptide powder, wherein wolfberry fruit powder and sheep liver polypeptide powder
Weight ratio is 1:1.When edible, 100mg wolfberry fruit powder and 1g sheep liver polypeptide powder (wherein sheep liver polypeptide accounting 10%) are taken, 10ml water is added
Dissolution, at this point, the 100mg of polypeptide containing sheep liver in 10ml solution.
Embodiment 2
A kind of benefit anahemin composition, is made of wolfberry fruit powder and sheep liver polypeptide powder, wherein wolfberry fruit powder and sheep liver polypeptide powder
Weight ratio is 1:0.7.When edible, 130mg wolfberry fruit powder and 0.91g sheep liver polypeptide powder (wherein sheep liver polypeptide accounting 10%) are taken, is added
10ml water dissolution, at this point, the 91mg of polypeptide containing sheep liver in 10ml solution.
Embodiment 3
A kind of benefit anahemin composition, is made, wherein the weight of fructus lycii and sheep liver polypeptide of wolfberry fruit powder and sheep liver polypeptide powder
Than being 1:1.3.When edible, 80mg wolfberry fruit powder and 1.04g sheep liver polypeptide powder (wherein sheep liver polypeptide accounting 10%) are taken, 10ml water is added
Dissolution, at this point, the 104mg of polypeptide containing sheep liver in 10ml solution.
Embodiment 4
A kind of benefit anahemin composition, is made, wherein the weight of fructus lycii and sheep liver polypeptide of wolfberry fruit powder and sheep liver polypeptide powder
Than being 1:0.8.When edible, 120mg wolfberry fruit powder and 0.96g sheep liver polypeptide powder (wherein sheep liver polypeptide accounting 10%) are taken, 10ml is added
Water dissolution, at this point, the 96mg of polypeptide containing sheep liver in 10ml solution.
Embodiment 5
A kind of benefit anahemin composition, is made of fructus lycii water extract and sheep liver polypeptid solution, can be concentrated and take orally for 10ml
The form of liquid uses, wherein every 10 milliliters of solution contains the water extract and sheep liver polypeptide 106.4mg of 103mg fructus lycii.
Wherein, fructus lycii water extract preparation method is as follows：103mg medlar powder is broken into thick last, as in tool plug bottle, added
20ml water is ultrasonically treated 45min under the conditions of 60 DEG C of bath temperature, filters, and collects filtrate to obtain the final product.
Embodiment 6
A kind of benefit anahemin composition, is made of fructus lycii water extract and sheep liver polypeptid solution, can be concentrated and take orally for 10ml
The form of liquid uses, wherein every 10 milliliters of solution contains the water extract and 92mg sheep liver polypeptide of 70.2mg fructus lycii.
Wherein, fructus lycii water extract preparation method is as follows：70.2mg medlar powder is broken into it is thick last, as in tool plug bottle,
Add 14ml water, be ultrasonically treated 45min under the conditions of 60 DEG C of bath temperature, filter, collect filtrate to obtain the final product.
Embodiment 7
A kind of benefit anahemin composition, is made of fructus lycii water extract and sheep liver polypeptid solution, can be concentrated and take orally for 10ml
The form of liquid uses, wherein every 10 milliliters of solution contains the water extract and 121.6mg sheep liver polypeptide of 90mg fructus lycii.
Wherein, fructus lycii water extract preparation method is as follows：90mg medlar powder is broken into thick last, as in tool plug bottle, added
18ml water is ultrasonically treated 45min under the conditions of 60 DEG C of bath temperature, filters, and collects filtrate to obtain the final product.
Embodiment 8
A kind of benefit anahemin composition, is made of fructus lycii water extract and sheep liver polypeptid solution, can be concentrated and take orally for 10ml
The form of liquid uses, wherein every 10 milliliters of solution contains the water extract and 98.8mg sheep liver polypeptide of 110mg fructus lycii.
Wherein, fructus lycii water extract preparation method is as follows：110mg medlar powder is broken into thick last, as in tool plug bottle, added
22ml water is ultrasonically treated 45min under the conditions of 60 DEG C of bath temperature, filters, and collects filtrate to obtain the final product.
In Examples 1 to 4, wolfberry fruit powder is ground into powder by pulverizer；Sheep liver polypeptide powder is prepared by the following method：Newly
Fresh sheep liver → finely divided processing → enzymatic hydrolysis → de- hardship → decoloration → ultrafiltration → drying → sheep liver polypeptide powder；Wherein enzymatic hydrolysis is using neutral
Protease takes off bitter use and takes off bitter enzyme, and decoloration and deodorization uses active carbon, and ultrafiltration is filtered using film, and drying is using spray drying process.Benefit
It is measured with conventional method (for the prior art, details are not described herein again), the small molecule sheep of active effect in the sheep liver polypeptide powder
Anahemin accounting is 10%.
In embodiment 5~8, sheep liver polypeptid solution is prepared by the following method：
(1) it takes new fresh sheep liver 1kg, removes fat, blood impurities, when sufficiently being washed to no watery blood, with beater homogenate,
Meat gruel is made, then according to 1:10 ratio is mixed with water, is stirred evenly, and adjusts pH8.0 with 20% sodium hydroxide solution,
Small peptide special protein enzyme 0.5 ‰ (V/W) is added under the conditions of 40 DEG C, hydrolyzes 3 hours, obtains first time hydrolyzate；
(2) it is 8 by first time hydrolyzate tune pH, compound protease (commercially available) is added and is digested；Compound protein enzyme dosage
It is the 0.2% of total protein used in step (1), enzymolysis time 3h；Enzyme deactivation after enzymatic hydrolysis, enzyme-removal temperature are 85 DEG C, when enzyme deactivation
Between 10 minutes；It is cooled to 60 DEG C after the completion of enzyme deactivation plus active carbon decolourizes, time 30min, filter to get filtrate i.e. sheep liver polypeptide
Aqueous solution, sheep liver content of peptides is 15.2g/L in sheep liver polypeptid solution at this time.
The effect of embodiment is explained below by experiment：
One, product sensory index
Liver protecting oral solution prepared by embodiment 5~8 is in pale red transparency liquid, free from admixture, no fishy smell, tool
There is distinctive taste smell, has light sweet taste.
Two, toxicological experiment
Mouse 50 are taken, is randomly divided into five groups of A, B, C, D, E, every group 10, wherein A group is fed prepared by embodiment 5
Oral solution, B group are fed with oral solution prepared by embodiment 6, and C group is fed with oral solution prepared by embodiment 7, and D group is fed to implement
Oral solution prepared by example 8, E group (blank group) are fed with deionized water, and dosage is daily 0.25ml/kg, and successive administration 30 days.
It is tested by nursing in 30 days, has no that animal subject has any toxicity damage to act on.
Three, clinical test
1, Testing index
According to liver function five indices numerical value change degree, to judge the drug effect of composition provided herein, wherein liver
Function five are specially：
Glutamic-pyruvic transaminase (ALT) is primarily present in hepatocyte cell matter, and normal value is 0~40, and liver is illustrated when higher
Damage；
Glutamic-oxalacetic transaminease (AST) is primarily present in liver cell mitochondria, and normal value is 0~40, and liver is illustrated when higher
It is serious to destroy, caused by such damage can be inflammation, it can also be caused by excessive drinking, drug etc.；
When bilirubin direct (DBil) is dead red blood cell or destruction, there is hemoglobin to be discharged into blood, normal value is
1.7~7umol/l illustrates that hepatic disease or red blood cell go to pot when higher；
Indirect bilirubin (IBil) is changed in liver by indirect bilirubin, is discharged from bile duct, and normal value is 1.7~
13.7umol/l illustrates that hepatic disease or biliary tract are obstructed when higher；
Total bilirubin (TBil) includes bilirubin direct and indirect bilirubin, and normal value is 1.7~17.1umol/l, higher
When jaundice symptom easily occurs.
2, test method
1) tested crowd one：Only five exception persons of liver function
20 liver function five indices exception persons (other body indexs are normal) are chosen as subject, be randomly divided into A,
Two groups of B, every group of 10 people, A group according to shown in embodiment 1 formula and edible way carry out, B group according to embodiment 5 formula into
Row is taken, and once a dose sooner or later, each 10ml, and continuous use 1 month.Before subject starts test and take test formulation 1
After a month, empty stomach blood drawing is carried out to subject respectively, is chemically examined, to check five indices of liver function.
2) tested crowd two：Slight first, second, hepatitis patient
Slight slight first, second, hepatitis patient each 5 are chosen, respectively according to formula shown in embodiment 1 and edible side
Formula carries out, and takes in the morning and evening, each 10ml continuously takes 1 month.Before subject starts test and take test formulation
After 1 month, empty stomach blood drawing is carried out to subject respectively, is chemically examined, to check five indices of liver function.
3, test result
10 subjects in A group are behind formula 1 month for taking that embodiment 1 provides, the five indices of full complement liver
Restore normal；
10 subjects in B group are taking given by embodiment 5 after formula 1 month, and five of full complement liver refer to
Mark restores normal.
15 slight first, second, hepatitis patients are improved using the rear state of an illness, and liver function index numerical value has decline.
Above-described is only some embodiments of the present invention.For those of ordinary skill in the art, not
Under the premise of being detached from the invention design, various modifications and improvements can be made, these belong to protection model of the invention
It encloses.
Claims (6)
1. beneficial anahemin composition, which is characterized in that be mainly made by following raw material：Fructus lycii and sheep liver polypeptide.
2. benefit anahemin composition according to claim 1, which is characterized in that the weight ratio of the fructus lycii and sheep liver polypeptide
It is 1:0.7-1.3.
3. benefit anahemin composition according to claim 2, which is characterized in that the weight ratio of the fructus lycii and sheep liver polypeptide
It is 1:1.
4. described in any item beneficial anahemin compositions according to claim 1~3, which is characterized in that the fructus lycii is wolfberry fruit powder
Or fructus lycii water extract.
5. benefit anahemin composition according to claim 4, which is characterized in that the sheep liver polypeptide is that sheep liver polypeptide is water-soluble
Liquid or sheep liver polypeptide powder.
6. benefit anahemin composition as claimed in claim 4 is preparing the application on liver protecting health care product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811087728.7A CN108813636A (en) | 2018-09-18 | 2018-09-18 | Beneficial anahemin composition and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811087728.7A CN108813636A (en) | 2018-09-18 | 2018-09-18 | Beneficial anahemin composition and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108813636A true CN108813636A (en) | 2018-11-16 |
Family
ID=64149365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811087728.7A Pending CN108813636A (en) | 2018-09-18 | 2018-09-18 | Beneficial anahemin composition and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108813636A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110432441A (en) * | 2019-08-05 | 2019-11-12 | 广东羲准生物科技有限公司 | Poria cocos sheep liver peptide composition and its application |
| CN111467471A (en) * | 2020-03-23 | 2020-07-31 | 广州中健中医药科技有限公司 | Preparation method and preparation of medicine and food dual-purpose preparation for relieving visual fatigue and improving eyesight |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1923026A (en) * | 2006-09-13 | 2007-03-07 | 灵武市泰运生化制品有限公司 | Preparation of liver peptide |
| CN108208496A (en) * | 2016-12-12 | 2018-06-29 | 锡林郭勒盟肽好生物制品有限责任公司 | The preparation method of blood sugar lowing polypeptide draft solid beverage and liver Gly-His-Lys |
-
2018
- 2018-09-18 CN CN201811087728.7A patent/CN108813636A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1923026A (en) * | 2006-09-13 | 2007-03-07 | 灵武市泰运生化制品有限公司 | Preparation of liver peptide |
| CN108208496A (en) * | 2016-12-12 | 2018-06-29 | 锡林郭勒盟肽好生物制品有限责任公司 | The preparation method of blood sugar lowing polypeptide draft solid beverage and liver Gly-His-Lys |
Non-Patent Citations (3)
| Title |
|---|
| 孟昭泉等: "《食物药物相宜相克大全》", 30 June 2007, 金盾出版社 * |
| 徐勤等: "肝肽的试制", 《四川食品与发酵》 * |
| 陈栋梁: "《多肽营养学》", 31 January 2006, 湖北科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110432441A (en) * | 2019-08-05 | 2019-11-12 | 广东羲准生物科技有限公司 | Poria cocos sheep liver peptide composition and its application |
| CN111467471A (en) * | 2020-03-23 | 2020-07-31 | 广州中健中医药科技有限公司 | Preparation method and preparation of medicine and food dual-purpose preparation for relieving visual fatigue and improving eyesight |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102293430B (en) | Beverage with functions of antioxidation and immunity enhancing, and preparation method thereof | |
| CN105106081B (en) | A kind of Chinese herbal toothpaste for oral inflammation and preparation method thereof | |
| CN108813636A (en) | Beneficial anahemin composition and its application | |
| CN106310236A (en) | Antioxidation SOD oral spray and preparing method thereof | |
| CN101297889A (en) | Chinese medicine preparation for treating foot-and-mouth disease and preparation method thereof | |
| CN109400750B (en) | Pharmaceutical composition with uric acid reducing effect | |
| CN105029568A (en) | Black garlic beverage and preparation method thereof | |
| CN106236875A (en) | A kind of Chinese medicine composition of liver heat removing and eyesight improving and preparation method thereof | |
| CN109589400B (en) | Composition with neuroprotective effect | |
| CN103301217B (en) | Composition and applications thereof, pharmaceutical preparation and health-care product | |
| CN110559391B (en) | Eye patch containing polygonatum polysaccharide | |
| CN111643646A (en) | Traditional Chinese medicine preparation for preventing and treating new coronary pneumonia and preparation method and application thereof | |
| CN105497059A (en) | Compound of caulis dendrobii extract and iron and preparing method and application of compound | |
| CN101503721B (en) | Method for extracting swan-mussel polysaccharide | |
| CN102416038B (en) | Traditional Chinese medicine composition for treating infantile recurrent respiratory tract infection | |
| CN105533737B (en) | A kind of black garlic oral solution and its preparation method and application containing Folium Artemisiae Argyi extract | |
| CN101559166B (en) | Ophiopogon japonicus extract, preparation method and hypoglycemic application thereof | |
| CN113693148A (en) | Liver-nourishing eyesight-improving health tea and preparation method thereof | |
| CN108542923A (en) | A kind of application from the melanin extracted in black fungus in liver-protecting product | |
| CN110184163A (en) | A kind of preparation method with the kudzuvine root wine for reducing hepatic injury function | |
| CN104706836B (en) | A kind of Chinese medicine composition of eliminating chloasma and its application and preparation method | |
| CN115944700B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN109055140B (en) | Brain-strengthening and liver-protecting cordial and preparation method thereof | |
| CN101912449B (en) | Medicament for treating hepatitis and preparation technology thereof | |
| CN106728666A (en) | Lysinepuzinc piece |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190510 Address after: 528200 Room 215, 7 Royal Fort International Business Center, 15 Shilong North Road, Guicheng Street, Nanhai District, Foshan City, Guangdong Province Applicant after: Guangdong Peptide Shijia Biotechnology Co., Ltd. Address before: 510000 4002 tower B tower 33, Zhongshan three road, Guangzhou, Guangdong, Yuexiu District Applicant before: Guangdong Xi Zhi Biotechnology Co., Ltd. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181116 |